Highlight 2 in lung cancer
In this video, Prof. Christophe Dooms from UZ Gasthuisberg in Leuven discussed several important studies presented at the conference. One of the studies mentioned was the Phase I LIBELULE Study, which is a randomized Phase III study evaluating the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
Another study highlighted was a Phase I study on YKA-029A, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The study aimed to assess the safety and efficacy of this inhibitor in patients.
The TRIDENT-1 Study was also discussed, which is a Phase II study investigating the activity of repotrectinib in advanced solid tumours harbouring ROS1 or NTRK1-3 rearrangements.
Prof. Dooms mentioned the PHAROS Study, an ongoing Phase II trial evaluating the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with metastatic BRAFV600-mutant non-small cell lung cancer (NSCLC). The study focuses on patients receiving this combination as either first- or second-line treatment.
Lastly, the CHECKMATE-9LA Study was addressed, which is a randomized Phase III study comparing the efficacy of nivolumab plus ipilimumab combined with platinum-doublet chemotherapy (two cycles) as a first-line treatment for metastatic NSCLC versus chemotherapy alone (four cycles).
With the educational support of:
